Condition: B-cell Malignancy · Relapsed Cancer · Refractory Cancer · Sponsor: BeOne Medicines
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
This description comes directly from the study's public registry record.
Study Director · 1.877.828.5568 · clinicaltrials@beonemed.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Phoenix | Phoenix, Arizona, United States | Recruiting |
| University of Southern California Norris Comprehensive | Los Angeles, California, United States | Recruiting |
| Mayo Clinic Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| The University of Kansas Cancer Center | Westwood, Kansas, United States | Recruiting |
| Mayo Clinic Rochester | Rochester, Minnesota, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Summit Medical Group | Florham Park, New Jersey, United States | Recruiting |
| Icahn School of Medicine At Mount Sinai | New York, New York, United States | Recruiting |
| Columbia University Medical Center | New York, New York, United States | Recruiting |
| Weill Cornell Medical College Newyork Presbyterian Hospital | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center Mskcc | New York, New York, United States | Recruiting |
+ 38 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06634589